NYSTATIN AND TRIAMCINOLONE ACETONIDE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
| Metabolism | Nystatin is not absorbed systemically and is excreted unchanged in feces. Triamcinolone acetonide is metabolized in the liver via CYP3A4, primarily to 6β-hydroxytriamcinolone and other metabolites. |
| Excretion | Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%). |
| Half-life | Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination. |
| Protein binding | Nystatin: negligible binding due to lack of systemic absorption. Triamcinolone acetonide: approximately 68% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Nystatin: not applicable (no systemic absorption). Triamcinolone acetonide: Vd approximately 1-2 L/kg after IM injection, reflecting extensive tissue distribution. |
| Bioavailability | Nystatin: oral bioavailability negligible (<5%) due to poor absorption from GI tract; intended for local effect only. Triamcinolone acetonide: topical bioavailability unknown but minimal due to poor percutaneous absorption (less than 1% of dose enters systemic circulation); after IM injection, bioavailability is 100%. |
| Onset of Action | Nystatin: oral suspension for oral candidiasis: clinical effect within 24-48 hours; topical for cutaneous candidiasis: improvement within 24-72 hours. Triamcinolone acetonide: topical anti-inflammatory effect begins within hours of application; maximal effect by 3-5 days. |
| Duration of Action | Nystatin: treatment typically requires 24-48 hours of application after lesions heal; duration depends on adequacy of therapy. Triamcinolone acetonide: topical effects last 6-12 hours after a single application; with occlusion, effect may be prolonged. |
| Molecular Weight | 580.71 |
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
| Dosage form | OINTMENT |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Apply thin layer to affected area twice daily. Safety and efficacy not established for children <2 years; limited data for older children. |
| Geriatric use | No specific adjustment; use caution due to skin thinning and potential for systemic absorption. |
| 1st trimester | Topical corticosteroids should be used during pregnancy only if potential benefit justifies potential risk. Nystatin is not absorbed; triamcinolone acetonide has been associated with low birth weight in animal studies with systemic exposure. Limited human data suggest no major malformations, but avoid prolonged use on large areas. |
| 2nd trimester | Same as first trimester; minimal systemic absorption with topical use, but caution advised due to corticosteroid component. |
| 3rd trimester | Same as first and second trimesters; avoid prolonged use on large areas or under occlusion to minimize systemic absorption. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Topical application results in minimal systemic absorption; however, corticosteroids can cross the placenta. Nystatin is poorly absorbed and not expected to reach significant fetal levels. Triamcinolone acetonide is absorbed percutaneously but placental transfer is limited with low maternal doses. |
■ FDA Black Box Warning
None
| Common Effects | Hyperglycemia |
| Serious Effects |
Hypersensitivity to nystatin, triamcinolone acetonide, or any component of the formulation
| Precautions | Prolonged use may lead to overgrowth of nonsusceptible organisms including bacteria and fungi, Avoid use in patients with known hypersensitivity to any component, In case of sensitization or irritation, treatment should be discontinued, Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia; use with caution in pediatric patients and over large areas or occlusive dressings |
| Food/Dietary | No clinically significant food interactions. |
Loading safety data…
| Breastfeeding | Topical application with minimal systemic absorption is likely compatible with breastfeeding. Avoid application to breast area to prevent infant ingestion. Use smallest amount for shortest duration. Nystatin is not absorbed; triamcinolone acetonide absorption is minimal with topical use. |
| Lactation Rating | L2 - Safer (limited data, likely safe) |
| Teratogenic Risk | Topical nystatin and triamcinolone acetonide: nystatin is not absorbed; triamcinolone acetonide has low systemic absorption from topical use. However, corticosteroids are generally considered to have potential fetal risk (cleft palate, growth restriction) if used systemically in first trimester. Topical use is considered low risk, but avoid prolonged use on large areas. FDA pregnancy category C; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required for topical use. If used chronically on large areas, monitor maternal blood pressure and blood glucose (steroid effect). Fetal monitoring not indicated. |
| Fertility Effects | No known adverse effects on fertility from topical nystatin/triamcinolone acetonide. Systemic corticosteroids may affect ovulation, but topical use has negligible systemic levels. |
| Clinical Pearls | Combination therapy for dermatophyte and Candida infections with concurrent inflammation; limited to 14 days to avoid steroid-induced skin atrophy and systemic absorption; not for ophthalmic, perioral, or vaginal use. |
| Patient Advice | Apply thin layer to affected area twice daily for up to 2 weeks. · Do not cover with bandages unless directed by your doctor. · Report signs of superinfection, skin thinning, or striae. · Avoid use on face, armpits, or groin unless instructed. |